There are common misconceptions among the diabetics that the diabetes drugs are almost safe for the patient having diabetic profile. This is quite considered as the medicines that are specially derived for the diabetic people. This holds good up to some extent, but it shall not be thought as the substitute for the extensive diabetes management and care that is advised by the medical practitioners. The drug that is at the sixth position in the list of top ten dangerous diabetes drugs is the category of the drugs in Dipeptidyl peptidase-4 inhibitors (DPP-4), sitagliptin (Januvia), saxagliptin (Onglyza) and linagliptin (Tradjenta).
These are considered as important diabetes care medicine as it acts as the insulin level enhancer that improves the physiological capacity of controlling the blood glucose. These are different in the mechanism as the drugs that are taken orally for controlling the blood glucose level. These drugs act on the pancreatic insulin secretion, reducing the glucagon secretion and provoking liver to reduce the glucose production.
The studies on the drugs indicate that these are having potential for treating the diabetes mellitus type 2 as these drugs are capable of controlling hormone level to maintain the blood glucose without lowering the glucose level. This reduces the risk of severe hypoglycemia and related symptoms.
How DPP4 Inhibitors Work?
These are known to inhibit the biochemical processes that are carried out by the incretin hormone in normal physiological conditions. On taking the DPP4 inhibitors the incretin hormone is not decomposed into further compounds as it naturally would be and stimulate the insulin production for a prolonged time and slow down the digestive process. The clinical studies suggest that these DPP-4 inhibitors can reduce the HbA1c for a considerable long period almost one year after the treatment. This helps in getting many advantages like low risk of hypoglycemia, consistent body weight, as well as increased regeneration of pancreatic beta cells.
Usage and Indications:
Keeping these advantages and the improved metabolic control in view these drugs were administered for studies in the diabetic patients to carry up the research about the side effects and other contraindication that are possible in the patients after taking this drug. The patients being treated with the drug over a period of 12 weeks were seen to develop the increased susceptibility to infections. These patients were administered the Sitagliptin and Vildagliptin. The studies being carried out on the long-term usage and the safety from the complication that may arise is still in process. Apart the usage of these drugs with the patients with other anti-diabetic drugs and their interference is also unrevealed. These all studies are to be carried out to establish the drug safety as per the clinical standards in the diabetes patients.
Side Effects of the drug:
The DPP-4 Inhibitors are required to be taken in strict medical supervision. The studies on the patients who have undergone the treatment with this drug are known to have side effects like as infection in the respiratory and urinary tract, increased chances of pancreatitis, hypertension, anemia, acute joint pain, headache, depression, fatigue and many others. The studies also indicate that the therapies like Onglyza may lead to pancreatic inflammation and the cancer of the pancreas.
Therefore any of the diabetic drugs shall be taken only after consulting your physician and within medical supervisions only.